Biomarkers in prostate cancer surveillance and screening: past, present, and future

Biomarkers in prostate cancer surveillance and screening: past, present, and future

Blog Article

The use of biomarkers for prostate cancer (PCa) screening, detection, and prognostication have revolutionized the diagnosis and management of the disease.Current clinical HID Ballast practice has been driven largely by the utilization of prostate-specific antigen (PSA).The lack of specificity of PSA for PCa has led to both unnecessary biopsies and overdiagnosis of indolent cancers.The recent controversial recommendation by the United States Preventive Services Task Force Natural Gas Dryer against PCa screening has highlighted the need for novel clinically useful biomarkers.We review the literature on PCa biomarkers in serum, urine, and tissue.

While these markers show promise, none seems poised to replace PSA, but rather may augment it.Further validation and consideration of how these novel markers improve clinical outcome is necessary.The discovery of new genetic markers shows promise in stratifying men with aggressive PCa.